Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Observational Studies01:11

Observational Studies

10.1K
Observational studies are a type of analytical study where researchers observe events without any interventions. In other words, the researcher does not influence the response variable or the experiment's outcome.
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
10.1K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

446
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
446
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

499
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
499
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

201
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
201
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

25
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
25
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

174
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
174

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomedical Large Language Models and Prompt Engineering for Causality Assessment of Individual Case Safety Reports in Pharmacovigilance.

Pharmaceutical research·2026
Same author

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium-glucose cotransporter 2 inhibitor users.

British journal of clinical pharmacology·2026
Same author

Early adoption patterns of the recombinant zoster vaccine: real-world versus clinical trial populations.

Infectious diseases (London, England)·2025
Same author

The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE-D) ISPE-Endorsed Guidance.

Pharmacoepidemiology and drug safety·2025
Same author

Sexual Dysfunction in Male Patients After Initiating Treatment with Antidepressants.

Drug safety·2025
Same author

Current Use of Common Data Models in the Nordic Countries.

Pharmacoepidemiology and drug safety·2025
Same journal

A Drug-Environment Interaction Between PM<sub>2</sub> <sub>.5</sub> Concentration and Corticosteroid Use on Cardiovascular and Thromboembolic Events in Older Adults.

Pharmacoepidemiology and drug safety·2026
Same journal

Association Between Socioeconomic Conditions and Biologic Prescriptions for Inflammatory Bowel Diseases in the Brazilian Public Healthcare System: An Ecological Study.

Pharmacoepidemiology and drug safety·2026
Same journal

Effectiveness of Metformin in Preventing Colorectal Cancer Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation.

Pharmacoepidemiology and drug safety·2026
Same journal

Trends in Pharmacist-Prescribed Dispensing Records of HIV Pre-Exposure (2020-2025) and Post-Exposure Prophylaxis (2020-2024) in Brazil: A Time Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

French Consumption of Methylphenidate in Primary Care From 2016 to 2023, Impact of Prescribing Policy Changes-A Time-Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study.

Pharmacoepidemiology and drug safety·2026
See all related articles

Related Experiment Video

Updated: Oct 17, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.7K

Pharmacological and epidemiological considerations while constructing treatment episodes using observational data: A

Laura Pazzagli1, Morten Andersen2, Maurizio Sessa2

  • 1Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Pharmacoepidemiology and Drug Safety
|October 6, 2021
PubMed
Summary
This summary is machine-generated.

Adding a gap time to treatment episodes in pharmacoepidemiology studies reduces overestimation of drug discontinuation and underestimation of outcome incidence. This ensures more accurate exposure assessment in real-world evidence research.

Keywords:
methodspermissible gappharmacoepidemiologytreatment episodes

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.3K

Related Experiment Videos

Last Updated: Oct 17, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.7K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.3K

Area of Science:

  • Pharmacoepidemiology
  • Health Services Research
  • Biostatistics

Background:

  • The permissible gap method is standard for defining continuous treatment use in pharmacoepidemiology.
  • This method uses redeemed drug amounts and defined gaps to establish treatment episodes.
  • Accurate definition of treatment episodes is crucial for reliable pharmacoepidemiological studies.

Purpose of the Study:

  • To compare the impact of including or excluding gap time at the end of treatment episodes.
  • To assess the effect on drug discontinuation and simulated outcome incidence rates.
  • To evaluate the magnitude of exposure time misclassification between the two methods.

Main Methods:

  • A simulated dataset of 100 patients and 1080 redeemed prescriptions was utilized.
  • Two approaches were compared: "gap+" (includes gap time) and "gap-" (excludes gap time).
  • A 90-day gap time was applied within a 365-day observational window.

Main Results:

  • "Gap+" resulted in longer median follow-up times (273 days) compared to "gap-" (183 days).
  • No discontinuation was observed with "gap+" in the first 100 days, versus 38 patients with "gap-".
  • The incidence rate ratio for the simulated outcome was 1.20 (95% CI: 0.72-2.02) favoring "gap+".

Conclusions:

  • Excluding gap time overestimates drug discontinuation, especially early in follow-up.
  • Excluding gap time underestimates the incidence rate of outcomes during exposure.
  • Including gap time provides a more accurate assessment of continuous medication use and associated outcomes.